在急性缺血性中风中早期抗血栓治疗
1Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
Journal of neuroendovascular therapy
|February 17, 2025
概括
阿司匹林是第二次中风预防的关键,在早期开始时减少死亡和残疾. 双重抗血小板治疗可能会增加超过三个月的出血风险.
科学领域:
- 神经学 神经学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗血栓治疗对于预防复发性缺血性中风至关重要.
- 阿司匹林被确立为二次中风预防,早期启动可以改善结果.
- 根据中风类型和患者因素,使用各种抗血小板剂和抗凝剂.
研究的目的:
- 审查当前针对急性缺血性中风的抗血栓治疗的现状.
- 突出阿司匹林和双抗血小板治疗 (DAPT) 的作用.
- 讨论针对特定中风病因的替代治疗方法和考虑.
主要方法:
- 临床试验和元分析的系统审查.
- 对抗血小板和抗凝剂使用的指导方针和现实数据的分析.
- 评估药物疗效,安全性和缺血性中风的具体适用情况.
主要成果:
- 早期开始服用阿司匹林 (160-300毫克/天在48小时内) 可以减少死亡或依赖.
- 双重抗血小板治疗 (阿司匹林和克洛皮多格雷尔) 在中风后21天至3个月有效.
- 扩展DAPT可能会增加出血风险;普拉苏格勒显示出潜力,但缺乏广泛的真实世界数据.
- 抗血小板药物可能会在心血管栓塞性中风中恶化出血事件;DOAC和华法林用于特定疾病.
结论:
- 阿司匹林仍然是预防二次缺血性中风的基石.
- DAPT提供短期收益,但需要仔细评估风险和收益.
- 治疗选择必须根据中风类型,并发症和出血风险进行个性化选择.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
597
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
597
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
457
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
457
01:16Clot Retraction and Fibrinolysis
3.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.5K